Additionally, a literature review by Liu et al. suggested that 1,25-(OH)2D3/vitamin D receptor (VDR) may be a good target for Systemic lupus erythematosus (SLE) therapy since it upregulated p27 expression while down-regulating S-phase kinase-associated protein 2 (Skp2) expression during SLE recovery [25]. The gene discussed is SKP2; the disease is systemic lupus erythematosus.